|
|
|
|
Novalar Goes After European Customers
San Diego-based Novalar Pharmaceuticals Inc.has signed an exclusive deal with pharmaceutical giant Sanofi-Aventis to market its dental anesthetic reversal agent in Germany. The move comes just a year after the company secured FDA approval for its drug, ...
|
|
|
Sanofi-Aventis and Novalar Enter Exclusive License Agreement to Commercialize OraVerse(R) in Germany
Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc.announced today that they have entered into an exclusive license and distribution agreement in which Sanofi-Aventis Deutschland will have the right to commercialize and market Novalar's ...
|
|
|
Sanofi-Aventis and Novalar sign licensing agreement
Sanofi-Aventis Deutschland and Novalar Pharmaceuticals have entered into an exclusive licensing and distribution agreement in which Sanofi-Aventis Deutschland will have the right to commercialize and market Novalar's OraVerse in Germany with options to...
|
|
|
Sanofi-Aventis and Novalar Enter Exclusive License Agreement to Commercialize OraVerse(R) in Germany
SAN DIEGO, March 3 /PRNewswire/ -- Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc.announced today that they have entered into an exclusive license and distribution agreement in which Sanofi-Aventis Deutschland will have the right to...
|
|
|
Sanofi-Aventis and Novalar Enter Exclusive License Agreement to Commercialize OraVerse(R) in Germany
Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc.announced today that they have entered into an exclusive license and distribution agreement in which Sanofi-Aventis Deutschland will have the right to commercialize and market Novalar's ...
|
|
|
Novalar Strikes Deal With Sanofi to Market Dental Drug in Germany, Maybe Rest of EU
Biotech , deals , startups Luke Timmerman wrote: Novalar has convinced one of the worlds biggest drugmakers, Paris-based Sanofi-Aventis, that it might be onto something.The San Diego-based biotech is announcing today that it has struck a partnership in which...
|
|
|
FDA Says Novalar Brochure for Dental Drug is Misleading
Biotech , Life Sciences , FDA Denise Gellene wrote: The FDA has told San Diego-based Novalar to stop using a misleading patient brochure promoting the companys injectible dental drug, phentolamine mesylate, which is intended to help dissipate the prolonged numb...
|
